📊 SYBX Key Takeaways
Is Synlogic, Inc.. (SYBX) a Good Investment?
SYNLOGIC is a pre-revenue biopharmaceutical company with zero commercial product sales, negative operating cash flow of -4.4M, and approximately 3-4 quarters of remaining cash runway at current burn rates. While the company maintains a strong balance sheet with 14.7M in cash and no debt, the lack of revenue, ongoing losses, and absence of insider buying activity indicate significant fundamental weakness and uncertainty regarding path to profitability.
Why Buy Synlogic, Inc.. Stock? SYBX Key Strengths
- Strong liquidity position with 4.30x current ratio and 14.7M cash on hand
- Zero debt burden with 0.00x Debt/Equity ratio
- Stable equity base of 11.9M with low liability burden of 1.4M
SYBX Stock Risks: Synlogic, Inc.. Investment Risks
- Zero revenue with 100% YoY decline - pre-revenue stage with no commercialized products
- Negative operating cash flow of -4.4M indicating rapid cash burn and uncertain path to profitability
- Limited cash runway of approximately 3-4 quarters at current burn rate before liquidity depletion
- No insider buying activity in last 90 days suggesting lack of management confidence
- Negative ROE (-8.5%) and ROA (-6.5%) reflect value destruction
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Clinical pipeline advancement and regulatory milestones for product candidates
- Time to first commercial revenue event and market acceptance
Synlogic, Inc.. (SYBX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.30x current ratio provides a solid financial cushion.
SYBX Profit Margin, ROE & Profitability Analysis
SYBX vs Healthcare Sector: How Synlogic, Inc.. Compares
How Synlogic, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Synlogic, Inc.. Stock Overvalued? SYBX Valuation Analysis 2026
Based on fundamental analysis, Synlogic, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Synlogic, Inc.. Balance Sheet: SYBX Debt, Cash & Liquidity
SYBX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Synlogic, Inc..'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-1.92 indicates the company is currently unprofitable.
SYBX Revenue Growth, EPS Growth & YoY Performance
SYBX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$117.0K | $-0.01 |
| Q2 2025 | N/A | -$212.0K | $-0.02 |
| Q1 2025 | N/A | $317.0K | $0.03 |
| Q3 2024 | N/A | -$117.0K | $-0.01 |
| Q2 2024 | N/A | $2.0M | $0.16 |
| Q1 2024 | $8.0K | -$15.6M | $-2.60 |
| Q3 2023 | $393.0K | -$12.1M | $-2.57 |
| Q2 2023 | $35.0K | -$15.0M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Synlogic, Inc.. Dividends, Buybacks & Capital Allocation
SYBX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Synlogic, Inc.. (CIK: 0001527599)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SYBX
What is the AI rating for SYBX?
Synlogic, Inc.. (SYBX) has an AI rating of STRONG SELL with 35% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SYBX's key strengths?
Claude: Strong liquidity position with 4.30x current ratio and 14.7M cash on hand. Zero debt burden with 0.00x Debt/Equity ratio.
What are the risks of investing in SYBX?
Claude: Zero revenue with 100% YoY decline - pre-revenue stage with no commercialized products. Negative operating cash flow of -4.4M indicating rapid cash burn and uncertain path to profitability.
What is SYBX's revenue and growth?
Synlogic, Inc.. reported revenue of $0.0.
Does SYBX pay dividends?
Synlogic, Inc.. does not currently pay dividends.
Where can I find SYBX SEC filings?
Official SEC filings for Synlogic, Inc.. (CIK: 0001527599) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SYBX's EPS?
Synlogic, Inc.. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SYBX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Synlogic, Inc.. has a STRONG SELL rating with 35% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SYBX stock overvalued or undervalued?
Valuation metrics for SYBX: ROE of -8.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SYBX stock in 2026?
Our dual AI analysis gives Synlogic, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SYBX's free cash flow?
Synlogic, Inc..'s operating cash flow is $-4.4M, with capital expenditures of $0.0.
How does SYBX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -8.5% (avg: 15%), current ratio 4.30 (avg: 2).